Hormone replacement therapy (HRT), breast cancer and tumor pathology.
Within an average observation period of 5-6 years, several clinical trials reported an increased risk of breast cancer due to hormone replacement therapy (HRT). However, it remains disputable, whether the increased rate of breast cancers detected within the given time frame is indeed due to newly induced tumors and thus constitutes HRT-initiated primary breast cancers. Onco-pathologically speaking it appears more likely that HRT stimulates the growth of already existing small tumor nests which - due to their small size - would otherwise go undiagnosed. The major arguments are: In summary, HRT is hence more likely to be a tumor promoter than a de novo-inducer of breast cancers.
Dietel
Manfred
M
Institut für Pathologie, Charité, Campus Mitte, Humboldt Universität Berlin, Charitéplatz 1, D-10117 Berlin, Germany. manfred.dietel@charite.de
D001943:Breast Neoplasms / Q000139:chemically induced* / Q000473:pathology; D002273:Carcinogens; D005260:Female; D020249:Hormone Replacement Therapy / Q000009:adverse effects*; D006801:Humans; D012307:Risk Factors
D002273:Carcinogens